iRhythm (IRTC) Q2 2026 earnings review
Record Margins and a Transformative Acquisition
iRhythm delivered a breakout quarter, growing revenue 20% YoY to $224.2M and driving spectacular operating leverage. Adjusted EBITDA margin surged to 19.3%, up 1,090 basis points from last year. Adding strategic fuel, the company announced the $287.5M acquisition of VitalConnect to expand into inpatient and multi-vitals monitoring, while simultaneously securing FDA clearance for a highly anticipated 3rd-generation AI algorithm. Management raised full-year guidance for both top and bottom lines, signaling confidence that this accelerated profitability is structurally sustainable.
🐂 Bull Case
Gross margin reached 72.8% while adjusted operating expenses stayed completely flat YoY at $145.0M. The company's 'one-to-many' primary care channel strategy is successfully delivering massive profit drop-through.
The VitalConnect acquisition gives iRhythm the missing pieces: a competitive MCT product, multi-vitals capability (11 parameters), and access to the hospital-to-home monitoring continuum.
🐻 Bear Case
Despite 'record profitability' in non-GAAP metrics, GAAP net loss was still -$0.4M due to a $14M securities class action settlement and another $4.9M in ongoing intellectual property litigation expenses.
Revenue growth has steadily cooled from 30.7% in 25Q3 to 27.1% in 25Q4, 25.7% in 26Q1, and now 20.1% in 26Q2. The law of large numbers is catching up to the core patch business.
⚖️ Verdict: 🟢
Bullish. The combination of flattening operating expenses, FDA clearance for a margin-boosting algorithm, and a smart, complementary acquisition paints a picture of a company rapidly maturing from a high-burn disruptor into a highly profitable platform.
Key Themes
Transformative VitalConnect Acquisition
iRhythm is acquiring VitalConnect for $287.5M ($237.5M cash, $50M stock). This is a masterstroke that instantly broadens iRhythm's addressable market. VitalConnect brings an FDA-cleared platform with multi-vitals (11 physiological parameters), up to 30-day wear, and live look-in capabilities. It shifts iRhythm from a pure-play ambulatory cardiac device company into the lucrative inpatient and remote patient monitoring (RPM) spaces.
3rd-Generation AI Algorithm Clearance
The FDA cleared iRhythm's next-generation algorithm, which management expects will reduce clinician review time by ~50%. This is the single biggest structural margin lever the company has, projected to drive ~$100M in cumulative cost savings over the next five years. This technological innovation directly insulates the gross margin profile as pricing pressures inevitably arise.
Operating Leverage Accelerating
Adjusted operating expenses were $145.0M in 26Q2, down slightly from $145.2M a year ago, even as revenue grew by $37.5M over the same period. The ability to hold OpEx completely flat while driving 20% top-line growth is staggering. It proves the integration into EHRs (like Epic) and the push into primary care networks is creating highly efficient, scalable volume.
Mounting Legal & Settlement Expenses
The GAAP vs. Non-GAAP bridge is carrying heavy baggage. Q2 results required adding back a $13.95M litigation settlement and $4.9M in intellectual property litigation expenses (related to the Baxter/Bardy Diagnostics suit). While backing these out reveals the core business's strength, shareholders are still paying the real cash cost of these ongoing legal battles.
Top-Line Decelerating
While 20.1% YoY revenue growth is objectively strong, the growth rate is decelerating from the mid-to-high 20s seen over the last year. This highlights the urgency of the VitalConnect acquisition—iRhythm needed a new growth vector as the core long-term Holter market begins to naturally mature.
Integration Execution Risk
iRhythm is taking on a highly complex integration with VitalConnect while simultaneously prepping the rollout of its next-gen MCT product (slated for H1 2027), deploying its new AI algorithm, and continuing to manage an active DOJ Civil Investigative Demand from prior years. Management bandwidth will be tested.
Macro Shift to Proactive Population Health
The company's success continues to be driven by a structural macro shift in U.S. healthcare: moving diagnostics out of the specialist's office (cardiology) and into primary care and value-based population health channels. Partnerships with entities like Desert Oasis Health Care using Predictive Arrhythmia Solutions underscore this migration toward preventative, AI-driven screening.
Other KPIs
Reversing sharply from a seasonal cash burn of -$33.1M in Q1, FCF jumped to $37.5M this quarter (more than double the $17.3M generated in 25Q2). This strong cash generation comfortably allows the company to fund the $237.5M cash portion of the VitalConnect deal from its $591.3M balance sheet without requiring new debt.
Accelerating from 70.9% in Q1 and 71.2% a year ago. The 160-basis point YoY improvement was driven by operational efficiencies, favorable product mix, and scale benefits. With the new AI algorithm poised to cut technician review times by half, this metric has a clear runway to stay in the mid-70s.
Guidance
Accelerating sequentially off the prior quarter's guide. Management bumped the full-year range up from $875-$885M. The midpoint of $885M implies a ~18.5% YoY growth rate against FY25 revenue of $747.1M, meaning the company expects current growth trends to remain highly stable through the back half of the year.
Accelerating significantly. The prior guidance provided in Q1 was 12.0%-13.0%. A full 100-basis point hike to the annual margin outlook mid-year is a massive signal of confidence in their operational cost controls and the immediate impact of gross margin initiatives.
Stable. The company explicitly noted that the VitalConnect acquisition is expected to be accretive to the revenue growth rate beginning in 2027, while perfectly preserving the previously communicated long-term 15% adjusted EBITDA margin target.
Key Questions
VitalConnect Integration & Cross-Selling
With the acquisition expected to close by the end of 2026, how quickly can the commercial organization begin cross-selling VitalConnect's multi-vitals and MCT capabilities into the existing Zio install base?
Algorithm P&L Impact
The 3rd-generation algorithm is expected to cut review time by 50% 'over time'. What is the specific phase-in timeline for these savings to hit the COGS line in late 2026 and early 2027?
Zio MCT Product Pipeline
How does the acquisition of VitalConnect's MCT capabilities alter the internal development and rollout timeline for the next-generation Zio MCT device originally slated for H1 2027?
DOJ Civil Investigative Demand
Are there any material updates regarding the DOJ's CID regarding the Zio AT product line from 2017-2022, and what legal costs should we model for the back half of the year?